Hangzhou Tigermed Consulting Co., Ltd
300347
อันดับในหุ้น
#3216
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides... Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
ราคาหุ้น
$7.44
มูลค่าตลาด
$5.49B
การเปลี่ยนแปลง (1 วัน)
-2.99%
การเปลี่ยนแปลง (1 ปี)
-0.42%
ประเทศ
CN
ซื้อขาย Hangzhou Tigermed Consulting Co., Ltd (300347)
หมวดหมู่
Healthcare
EPS สำหรับ Hangzhou Tigermed Consulting Co., Ltd (300347)
EPS ณ วันที่ June 2026 TTM: $0.01
จากรายงานทางการเงินล่าสุดและราคาหุ้นของ Hangzhou Tigermed Consulting Co., Ltd EPS ปัจจุบันของบริษัท (TTM) คือ $0.01 สิ้นปี 2024 บริษัทมี EPS เท่ากับ $0.06 น้อยกว่ารายได้ในปี EPS ในปี 2023 ซึ่งอยู่ที่ $0.33
ประวัติ EPS ของ Hangzhou Tigermed Consulting Co., Ltd ตั้งแต่ 2009 ถึง 2026
EPS ณ สิ้นแต่ละปี
| ปี | EPS | เปลี่ยน |
|---|---|---|
| 2026 (TTM) | $0.01 | -92.00% |
| 2025 | $0.15 | 130.75% |
| 2024 | $0.06 | -80.52% |
| 2023 | $0.33 | -36.52% |
| 2022 | $0.52 | 54.63% |
| 2020 | $0.34 | 107.52% |
| 2019 | $0.16 | 77.18% |
| 2018 | $0.09 | 45.40% |
| 2017 | $0.06 | 118.75% |
| 2016 | $0.03 | -22.16% |
| 2015 | $0.04 | 20.52% |
| 2014 | $0.03 | 24.29% |
| 2013 | $0.02 | 18.75% |
| 2012 | $0.02 | 32.48% |
| 2011 | $0.02 | 55.45% |
| 2010 | $0.01 | 260.71% |
| 2009 | 0.00 | 0.00% |
EPS สำหรับบริษัทหรือคู่แข่งที่คล้ายกัน
| บริษัท | EPS | ความแตกต่างของ EPS | ประเทศ |
|---|---|---|---|
| $17.32 | 144,233.33% |
US
|
|
| $-7.98 | -66,600.00% |
US
|
|
| $-5.29 | -44,183.33% |
AU
|
|
| $12.97 | 107,990.00% |
BE
|
|
| $27.74 | 231,066.67% |
NL
|
